Osteotec Announces Exclusive UK and Ireland Distribution Agreement With SI-BONE
Osteotec Announces Exclusive UK and Ireland Distribution Agreement With SI-BONE
NEWBURY, England, May 16, 2024 /PRNewswire/ -- Osteotec, the market-leading manufacturer and distributor of medical devices, is pleased to announce a new partnership with SI-BONE to exclusively distribute the iFuse Implant System in the UK and Ireland.
英國紐伯裏，2024年5月16日 /PRNewswire/ — 市場領先的醫療器械製造商和分銷商Osteotec欣然宣佈與SI-BONE建立新的合作伙伴關係，在英國和愛爾蘭獨家分銷iFuse植入系統。
The strategic relationship is the newest addition to Osteotec's rapidly expanding offering to customers, which provides surgeons with innovative solutions.
這種戰略關係是Osteotec快速擴展的客戶服務的最新補充，爲外科醫生提供了創新的解決方案。
San Jose, California-based SI-BONE are at the forefront of advancing minimally invasive procedures for the sacroiliac (SI) joint. The iFuse Implant System is designed to provide immediate SI joint stabilisation and allow long-term fusion.
總部位於加利福尼亞州聖何塞的SI-BONE處於推進骶（SI）關節微創手術的最前沿。iFuse 植入系統旨在提供即時的 SI 關節穩定並允許長期融合。
To date, more than 55,000 minimally invasive surgical SI joint fusions have been performed with the iFuse Implant System by more than 2,400 surgeons worldwide.
迄今爲止，全球已有2,400多名外科醫生使用iFuse植入系統進行了超過55,000次微創手術SI關節融合術。
"We are pleased to be expanding our product offering to include the iFuse Implant System, and to be working with the UK's top spine surgeons to give them more options, expand our treatment offering and deliver better patient outcomes," said Dean Stockwell, Osteotec Sales & Marketing Director.
Osteotec銷售與營銷總監迪恩·斯托克韋爾表示：“我們很高興能夠擴大產品範圍，將iFuse植入系統包括在內，並與英國頂級脊柱外科醫生合作，爲他們提供更多選擇，擴大我們的治療範圍並提供更好的患者療效。”
"Our customers have come to anticipate forward-thinking solutions from Osteotec, and this is just one more example of how we are increasing patient treatment options through investment in partnerships with manufacturers who share our values.
“我們的客戶已經開始期待Osteotec的前瞻性解決方案，這只是我們如何通過投資與認同我們價值觀的製造商建立合作伙伴關係來增加患者治療選擇的又一個例子。
"We look forward to working with the SI-BONE team to increase and support sales through our expertise, ensuring our customers enjoy the best possible experience, service, and support in the industry."
“我們期待與SI-BONE團隊合作，通過我們的專業知識增加和支持銷售，確保我們的客戶享受業內最佳的體驗、服務和支持。”
The SI joint is one of the most under-served, under-diagnosed, and under-treated areas in orthopaedics. The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.
SI 關節是骨科服務最差、診斷不足和治療最差的部位之一。iFuse Implant System 適用於骶融合術，用於治療包括骶關節功能障礙（直接由骶關節受損和退行性骶骨炎）引起的骶融合術。
It is anticipated that the agreement, which went into effect on April 1, 2024, will contribute to substantial increases in sales and revenue and accelerate growth.
預計該協議於2024年4月1日生效，將有助於銷售和收入的大幅增長並加速增長。
"We are excited about working with Osteotec to expand our footprint in the UK and Ireland," said Neville Lorimer, SI-BONE Vice President, International.
SI-BONE國際副總裁內維爾·洛裏默表示：“我們很高興能與Osteotec合作擴大我們在英國和愛爾蘭的足跡。”
"With the assistance of Osteotec's talented commercial team and extensive industry knowledge, we will be able to accelerate our strategic objective of providing superior patient outcomes in these markets."
“在Osteotec才華橫溢的商業團隊和豐富的行業知識的協助下，我們將能夠加快實現我們在這些市場提供卓越患者療效的戰略目標。”
The two organisations look forward to combining their expertise and technologies to maximise marketing opportunities, increase productivity and improve healthcare outcomes.
這兩個組織期待結合他們的專業知識和技術，最大限度地利用營銷機會，提高生產力並改善醫療保健成果。
"This exclusive distribution agreement builds upon the shared values of both companies and will give our customers more focused support than ever before," said Dean Stockwell. "We are pleased to be collaborating with an organisation that values excellence as much as we do."
迪恩·斯托克韋爾說：“這項獨家分銷協議建立在兩家公司的共同價值觀基礎上，將爲我們的客戶提供比以往任何時候都更加集中的支持。”“我們很高興能與一個像我們一樣重視卓越的組織合作。”
Editor's Notes
編者注
About Osteotec
關於 Osteotec
Osteotec is a manufacturer and distributor of medical devices headquarter in Newbury, UK, with offices in Dublin and Malmö. Established in 1993, Osteotec has been supplying into the NHS and private healthcare sectors for the past 31 years.
Osteotec是一家醫療器械的製造商和分銷商，總部位於英國紐伯裏，在都柏林和馬爾默設有辦事處。Osteotec成立於1993年，在過去的31年中一直爲國民保健服務和私人醫療保健行業提供產品。
Osteotec manufactures and distributes the Osteotec Silicone Finger, ChiroKlip and the Concentric Bone Graft System and is the exclusive UK distributor for world-leading orthopaedic partners including SI-BONE, TriMed, Enovis and Mathys.
Osteotec生產和分銷Osteotec硅膠手指、ChiroKlip和同心骨移植系統，並且是包括SI-BONE、TriMed、Enovis和Mathys在內的世界領先骨科合作伙伴的英國獨家分銷商。
Media Contact:
媒體聯繫人：
Ric Sumner
Head of Marketing
[email protected] | 020 3011 5574
For more information, visit –
裏克·薩姆納
營銷主管
[電子郵件保護] | 020 3011 5574
欲了解更多信息，請訪問—
About SI-BONE
關於 SI-BONE
SI-BONE is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive surgery of the SI joint in 2009, SI-BONE has supported over 3,600 surgeons in performing a total of more than 95,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including two randomized controlled trials and over 125 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.
SI-BONE 是骶骨盆解剖結構肌肉骨骼疾病外科治療技術的全球領導者。自2009年率先進行脊柱關節微創手術以來，SI-BONE已支持3,600多名外科醫生進行了總共超過95,000例骶骨盆手術。大量獨特的臨床證據支持使用SI-BONE的技術，包括兩項隨機對照試驗和超過125份同行評審出版物。SI-BONE利用其在微創SI關節融合術方面的領導地位，爲鄰近市場商業化了新的解決方案，包括成人畸形、脊柱固定和骨盆創傷。
For additional information on the company or the products including risks and benefits, please visit .
有關公司或產品的更多信息，包括風險和收益，請訪問。
Logo:
徽標：
SOURCE Osteotec
來源 Osteotec
譯文內容由第三人軟體翻譯。